Bicara chases Merus
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
Immutep stumbles on into phase 3
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.
The month ahead: July’s upcoming events
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
Merck’s big ADC deal takes a blow
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
Investors don't buy Lyell's solid tumour Car-T success
The ROR1 data are sketchy, and lung toxicity clouds prospects.
Lilly takes two shots at the Nectin goal
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
IO Biotech looks for an interim injection
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
